Breaking Finance News

Citigroup Inc. downgraded Quintiles IMS Holdings Inc (NYSE:Q) to Market Perform in a report released earlier today.

Having a price of $76.83, Quintiles IMS Holdings Inc (NYSE:Q) traded -4.99% lower on the day. With the last close up -0.77% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Quintiles IMS Holdings Inc has recorded a 50-day average of $75.98 and a two hundred day average of $73.57. Volume of trade was up over the average, with 5,998,122 shares of Q changing hands over the typical 1,541,710

Citigroup Inc. has downgraded Quintiles IMS Holdings Inc (NYSE:Q) to Market Perform in a statement released on 12/01/2016.

On Wednesday November 30, 2016, Barclays Capital released a statement on Quintiles IMS Holdings Inc (NYSE:Q) upped the target price from $0.00 to $90.00 that suggested an upside of 0.15%.

Performance Chart

Quintiles IMS Holdings Inc (NYSE:Q)

With a total market value of $0, Quintiles IMS Holdings Inc has price-earnings ratio of 22.45 with a one year low of $55.01 and a one year high of $81.45 .

A total of 15 analysts have released a research note on Quintiles IMS Holdings Inc. Eight analysts rating the company a strong buy, nine analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $76.50.

More About Quintiles IMS Holdings Inc (NYSE:Q)

Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *